AR108819A2 - Formas polimórficas de un inhibidor macrocíclico de vhc - Google Patents

Formas polimórficas de un inhibidor macrocíclico de vhc

Info

Publication number
AR108819A2
AR108819A2 ARP170101687A ARP170101687A AR108819A2 AR 108819 A2 AR108819 A2 AR 108819A2 AR P170101687 A ARP170101687 A AR P170101687A AR P170101687 A ARP170101687 A AR P170101687A AR 108819 A2 AR108819 A2 AR 108819A2
Authority
AR
Argentina
Prior art keywords
polymorphic forms
hcv inhibitor
macrocyclic hcv
macrocyclic
crystalline forms
Prior art date
Application number
ARP170101687A
Other languages
English (en)
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38229348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR108819(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of AR108819A2 publication Critical patent/AR108819A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proveen formas cristalinas del compuesto de la fórmula (1), el cual es un inhibidor macrocíclico de VHC, procesos para la preparación del mismo, y composiciones farmacéuticas que comprenden dichas formas cristalinas.
ARP170101687A 2007-02-01 2017-06-19 Formas polimórficas de un inhibidor macrocíclico de vhc AR108819A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07101563 2007-02-01

Publications (1)

Publication Number Publication Date
AR108819A2 true AR108819A2 (es) 2018-09-26

Family

ID=38229348

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080100427A AR065136A1 (es) 2007-02-01 2008-02-01 Formas polimorficas de un inhibidor macrociclico de vhc. procesos de obtencion y composiciones farmaceuticas.
ARP170101687A AR108819A2 (es) 2007-02-01 2017-06-19 Formas polimórficas de un inhibidor macrocíclico de vhc

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP080100427A AR065136A1 (es) 2007-02-01 2008-02-01 Formas polimorficas de un inhibidor macrociclico de vhc. procesos de obtencion y composiciones farmaceuticas.

Country Status (25)

Country Link
US (1) US8143402B2 (es)
EP (1) EP2118098B1 (es)
JP (1) JP5523110B2 (es)
KR (1) KR101580226B1 (es)
CN (3) CN101589040A (es)
AR (2) AR065136A1 (es)
AU (1) AU2008209696B2 (es)
BR (1) BRPI0806945A2 (es)
CA (1) CA2677170C (es)
CL (1) CL2008000321A1 (es)
CY (1) CY1116339T1 (es)
DK (1) DK2118098T3 (es)
ES (1) ES2524784T3 (es)
HK (2) HK1137438A1 (es)
HR (1) HRP20141137T1 (es)
IL (1) IL199215A (es)
MX (1) MX2009008275A (es)
NZ (1) NZ577568A (es)
PL (1) PL2118098T3 (es)
PT (1) PT2118098E (es)
RU (1) RU2533830C2 (es)
SI (1) SI2118098T1 (es)
TW (1) TWI423968B (es)
WO (1) WO2008092954A2 (es)
ZA (1) ZA200905377B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
DK2401272T3 (en) * 2009-02-27 2017-02-27 Janssen Pharmaceuticals Inc AMORF SALT OF A MACROCYCLIC INHIBITOR OF HCV
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
WO2011017389A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
PL2528922T3 (pl) 2010-01-27 2018-01-31 Ab Pharma Ltd Związki poliheterocykliczne jako inhibitory hcv
CN103380132B (zh) 2010-12-30 2016-08-31 益安药业 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂
JP2014502620A (ja) 2010-12-30 2014-02-03 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状ｃ型肝炎セリンプロテアーゼ阻害剤
TW201309690A (zh) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
BR112013027642A2 (pt) * 2011-05-04 2016-07-26 Merck Sharp & Dohme substância medicamentosa, composição farmacêutica, processo para isolar uma substância medicamentosa, e, usos da substância medicamentosa, do processo, e da composição farmacêutica
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2857705A1 (en) 2011-06-16 2012-12-20 AB Pharma Ltd. Macrocyclic heterocyclic compounds for inhibiting hepatitis c virus and preparation and use thereof
MX347855B (es) 2011-09-16 2017-05-16 Sanofi Sa Derivados de anilina, su preparación y su aplicación terapéutica.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8809265B2 (en) 2011-10-21 2014-08-19 Abbvie Inc. Methods for treating HCV
DK2583677T1 (da) 2011-10-21 2015-01-19 Abbvie Inc Fremgangsmåder til behandling af HCV omfattende mindst to direktevirkende antivirale midler, ribavirin, men ikke inteferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
KR20150074051A (ko) 2012-10-19 2015-07-01 브리스톨-마이어스 스큅 컴퍼니 C형 간염 바이러스 억제제
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
WO2015109925A1 (zh) * 2014-01-21 2015-07-30 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
WO2015180253A1 (zh) * 2014-05-29 2015-12-03 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
CZ2015220A3 (cs) * 2015-03-27 2016-10-05 Zentiva, K.S. Amorfní sůl makrocyklického inhibitoru viru hepatitidy C
WO2016177625A1 (en) 2015-05-04 2016-11-10 Sandoz Ag Amorphous simeprevir potassium
CN105503851B (zh) * 2015-12-09 2017-06-23 重庆润生科技有限公司 一种烯基噻唑衍生物的制备方法
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004211637C1 (en) * 2003-02-07 2010-08-19 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
AU2004276281A1 (en) * 2003-09-26 2005-04-07 Schering Corporation Macrocyclic inhibitors of hepatitis C virus NS3 serine protease
TWI375679B (en) * 2003-10-14 2012-11-01 Hoffmann La Roche Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
ES2336009T3 (es) * 2004-01-30 2010-04-07 Medivir Ab Inhibidores de la ns-3 serina proteasa del vhc.
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c

Also Published As

Publication number Publication date
DK2118098T3 (en) 2014-12-08
MX2009008275A (es) 2009-08-12
CA2677170C (en) 2017-04-18
HK1205125A1 (en) 2015-12-11
TWI423968B (zh) 2014-01-21
RU2009132660A (ru) 2011-03-10
CN105037347B (zh) 2018-06-01
US20100029715A1 (en) 2010-02-04
CN104230918B (zh) 2018-01-26
SI2118098T1 (sl) 2015-01-30
HRP20141137T1 (hr) 2015-01-30
CY1116339T1 (el) 2017-02-08
ZA200905377B (en) 2010-10-27
CA2677170A1 (en) 2008-08-07
AR065136A1 (es) 2009-05-20
WO2008092954A2 (en) 2008-08-07
EP2118098B1 (en) 2014-09-24
KR20090115929A (ko) 2009-11-10
ES2524784T3 (es) 2014-12-12
KR101580226B1 (ko) 2015-12-24
CN101589040A (zh) 2009-11-25
PT2118098E (pt) 2014-12-09
IL199215A (en) 2015-10-29
CN104230918A (zh) 2014-12-24
US8143402B2 (en) 2012-03-27
CN105037347A (zh) 2015-11-11
CL2008000321A1 (es) 2008-08-22
HK1137438A1 (en) 2010-07-30
WO2008092954A3 (en) 2008-10-02
WO2008092954A8 (en) 2009-12-23
TW200846347A (en) 2008-12-01
JP5523110B2 (ja) 2014-06-18
RU2533830C2 (ru) 2014-11-20
EP2118098A2 (en) 2009-11-18
AU2008209696A1 (en) 2008-08-07
AU2008209696B2 (en) 2013-05-09
PL2118098T3 (pl) 2015-03-31
JP2010517971A (ja) 2010-05-27
BRPI0806945A2 (pt) 2014-05-06
NZ577568A (en) 2012-02-24

Similar Documents

Publication Publication Date Title
AR108819A2 (es) Formas polimórficas de un inhibidor macrocíclico de vhc
ECSP10010722A (es) Compuestos orgánicos
GT200600341A (es) Inhibidores macrociclicos del virus de la hepatitis c
RS52534B (en) MACROCYCLIC COMPOUNDS OF HINOXALINE AS HCV NS3 PROTEASE INHIBITORS
NO20080784L (no) Histondeacetylaseinhibitorer
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
ME01992B (me) Jedinjenje diarilhidantoina
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CL2008000946A1 (es) Compuestos derivados de pirrolopirimidina, inhibidores de cianasa jak3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de rechazo de transplantes, enfermedades autoinmun
NI200800294A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmacéuticas que la contienen.
UA94833C2 (en) Substituted bicyclolactams
CU23616B7 (es) Forma cristalina gamma del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
CL2008001005A1 (es) Compuestos derivados de azufre, inhibidores de la serina proteasa ns3 del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos asociados a la proteasa de hcv.
RS52255B (en) NALMEFEN HYDROCHLORIDE DIHYDRATE
CL2007003540A1 (es) Compuestos derivados de macrociclos, inhibidores de la proteasa serina de hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
AR062211A1 (es) Derivados de 6-carboxi-normorfinano. composiciones farmaceuticas
CU23889B1 (es) 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para su producción y su uso como agentes antinflamatorios
NO20091817L (no) Kinase inhibitorer
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
GT200600173A (es) Forma purificada de tranaproget
EA200702587A1 (ru) Способ синтеза промежуточных продуктов, предназначенных для получения трициклических бензимидазолов
AR052488A1 (es) Derivados de 2-quinolonas como inhibidores de fosfodiesterasas
ECSP088374A (es) Formulacion de aerosol para inhalacion
GT200600102A (es) Procedimiento para la preparacion de compuestos benzoxazol sustituidos

Legal Events

Date Code Title Description
FB Suspension of granting procedure